{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-003906","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.942252+00:00","generated_at":"2026-06-20T03:51:04.282085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Roivant reports preliminary Q3 cash ~$1.5B; VTAMA revenue guided $9.0-9.5M","bullets":["Cash, cash equivalents and restricted cash ~$1.5B at Dec 31, 2022; pro-forma $1.7B after expected $115M Myovant proceeds.","Net product revenues from VTAMA expected $9.0M to $9.5M for Q3 ending Dec 31, 2022.","Myovant transaction with Sumitomo Pharma expected to close by March 31, 2023.","Preliminary unaudited results; final Q3 2022 financials to be reported in subsequent SEC filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-003906","json":"https://secwatch.observer/filing/0001140361-23-003906.json","markdown":"https://secwatch.observer/filing/0001140361-23-003906.md","text":"https://secwatch.observer/filing/0001140361-23-003906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/ny20006513x3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:51:04.282085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d852e0522b9319861d45980546afcb86d8d96b0e","claim":"Roivant Sciences Ltd. reported the third quarter ended December 31, 2022 results: revenue between $9.0 million and $9.5 million.","evidence_excerpt":"In addition, for the third quarter ended December 31, 2022, the Company expects to report between $9.0 million and $9.5 million in net product revenues from VTAMA. This information is preliminary and unaudited and reflects the Company’s estimated financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended December 31, 2022"},{"label":"Revenue","value":"between $9.0 million and $9.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}